Belarus Pharmaceuticals and Healthcare Report Q2 2014

Business Monitor International
March 19, 2014
84 Pages - SKU: BMI5217931
Countries covered: Belarus

Belarus Pharmaceuticals and Healthcare Report Q2 2014

BMI View: Pharmaceutical sales in Belarus are poised to recover as the fallout from the breaking of thepotash joint venture Uralkai-Belaruskali subsides, and the risk of currency devaluation temporarily relents.

However, Belarus must now contend with the consequences of Ukrainian instability and the impact of thison the region's economies. There are significant downside risks to our forecast for 2014, due to the threat offurther currency depreciation, a collapse in exports and absolute erosion of consumer purchasing power.

Headline Expenditure Projections

Pharmaceuticals: BYR8,927bn in 2013 (US$1.00bn) to BYR10,783bn (US$1.08mn) in 2014; +20.8% inlocal currency terms and +7.9% in US dollar terms.

Healthcare: BYR24,909bn (US$2.80bn) in 2013 to BYR28,874bn (US$2.90bn) in 2014; +15.9% in localcurrency terms and +3.5% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Pharmaceuticals and Healthcare Report - Russia Q4 2104 by Business Monitor International
BMI View: Russia's cooling of relations with the West is putting pressure on foreign investment in thecountry. With the EU and the US applying further ...
Pharmaceuticals and Healthcare Report - Greece Q4 2104 by Business Monitor International
BMI View: The pharmaceutical and healthcare industry in Greece will continue to contract over theremainder of 2014. The government will seek to reduce public spending ...
Pharmaceuticals and Healthcare Report - Finland Q4 2104 by Business Monitor International
BMI View: An ageing population and the subsequent increased consumption of high-value prescriptionmedicines for the treatment of long-term illnesses will place a greater strain on ...
Pharmaceuticals and Healthcare Report - Oman Q4 2014 by Business Monitor International
BMI View: Despite its small size in comparison with other GCC countries, Oman will remain an attractivemarket to multinational pharmaceutical companies due to the high ...
See all reports like this >>

More Belarus Prescription Drugs reports

Pharmaceuticals and Healthcare Report - Belarus Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Belarus Q4 2014BMI View: The Belarusian market will suffer from the impact of prolonged rouble depreciation andeconomic instability. ...
Belarus Pharmaceuticals and Helathcare Report Q3 2012 by Business Monitor International
BMI View: The short-term outlook for the Belarusian pharmaceutical market is deeply uncertain due toexchange-rate volatility and the economy’s lack of capacity for progress without ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!